| 18.92 -1.04 (-5.21%) | 02-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 26.14  |
1-year : | 28.72 |
| Resists | First : | 22.38 |
Second : | 24.59 |
| Pivot price | 21.18 |
|||
| Supports | First : | 18.81 |
Second : | 15.65 |
| MAs | MA(5) : | 20.43 |
MA(20) : | 21.48 |
| MA(100) : | 20.35  |
MA(250) : | 13.76 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 17.1 |
D(3) : | 23.8 |
| RSI | RSI(14): 36.8 |
|||
| 52-week | High : | 26.39 | Low : | 6.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RCUS ] has closed below the lower bollinger band by 7.4%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 13.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 20.55 - 20.68 | 20.68 - 20.77 |
| Low: | 18.53 - 18.68 | 18.68 - 18.79 |
| Close: | 18.72 - 18.94 | 18.94 - 19.1 |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.
Fri, 13 Feb 2026
Arcus Biosciences (NYSE:RCUS) Rating Lowered to "Hold" at Wells Fargo & Company - MarketBeat
Thu, 12 Feb 2026
RCUS: Wells Fargo Downgrades Arcus Biosciences, Lowers Price Tar - GuruFocus
Thu, 12 Feb 2026
What Analysts Are Saying About Arcus Biosciences Stock - Benzinga
Thu, 12 Feb 2026
Candriam S.C.A. Takes $5.15 Million Position in Arcus Biosciences, Inc. $RCUS - MarketBeat
Wed, 11 Feb 2026
Cancer drug developer Arcus sets Feb. 25 call on 2025 results - Stock Titan
Wed, 04 Feb 2026
Wall Street Analysts See a 57.56% Upside in Arcus Biosciences (RCUS): Can the Stock Really Move This High? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 124 (M) |
| Shares Float | 76 (M) |
| Held by Insiders | 30 (%) |
| Held by Institutions | 60.6 (%) |
| Shares Short | 8,900 (K) |
| Shares Short P.Month | 7,830 (K) |
| EPS | -3.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.07 |
| Profit Margin | -142.1 % |
| Operating Margin | -546.2 % |
| Return on Assets (ttm) | -21.1 % |
| Return on Equity (ttm) | -68.2 % |
| Qtrly Rev. Growth | -45.8 % |
| Gross Profit (p.s.) | -2.13 |
| Sales Per Share | 1.93 |
| EBITDA (p.s.) | -2.95 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -462 (M) |
| Levered Free Cash Flow | -139 (M) |
| PE Ratio | -5.74 |
| PEG Ratio | 0 |
| Price to Book value | 4.64 |
| Price to Sales | 9.75 |
| Price to Cash Flow | -5.07 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|